BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36870373)

  • 21. CYP17A1-independent production of the neurosteroid-derived 5α-pregnan-3β,6α-diol-20-one in androgen-responsive prostate cancer cell lines under serum starvation and inhibition by Abiraterone.
    de Mello Martins AGG; Allegretta G; Unteregger G; Haupenthal J; Eberhard J; Hoffmann M; van der Zee JA; Junker K; Stöckle M; Müller R; Hartmann RW; Ohlmann CH
    J Steroid Biochem Mol Biol; 2017 Nov; 174():183-191. PubMed ID: 28890368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and Structure-Activity Relationships of Novel Non-Steroidal CYP17A1 Inhibitors as Potential Prostate Cancer Agents.
    Wróbel TM; Rogova O; Sharma K; Rojas Velazquez MN; Pandey AV; Jørgensen FS; Arendrup FS; Andersen KL; Björkling F
    Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oxazole-Based Compounds As Anticancer Agents.
    Chiacchio MA; Lanza G; Chiacchio U; Giofrè SV; Romeo R; Iannazzo D; Legnani L
    Curr Med Chem; 2019; 26(41):7337-7371. PubMed ID: 30501590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors.
    Bonomo S; Hansen CH; Petrunak EM; Scott EE; Styrishave B; Jørgensen FS; Olsen L
    Sci Rep; 2016 Jul; 6():29468. PubMed ID: 27406023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling.
    Moll JM; Kumagai J; van Royen ME; Teubel WJ; van Soest RJ; French PJ; Homma Y; Jenster G; de Wit R; van Weerden WM
    Prostate; 2019 Jun; 79(9):937-948. PubMed ID: 31017696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. De novo steroid biosynthesis in human prostate cell lines and biopsies.
    Sakai M; Martinez-Arguelles DB; Aprikian AG; Magliocco AM; Papadopoulos V
    Prostate; 2016 May; 76(6):575-87. PubMed ID: 26841972
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and evaluation of naphthalene-based thiosemicarbazone derivatives as new anticancer agents against LNCaP prostate cancer cells.
    Altintop MD; Sever B; Özdemir A; Kuş G; Oztopcu-Vatan P; Kabadere S; Kaplancikli ZA
    J Enzyme Inhib Med Chem; 2016; 31(3):410-6. PubMed ID: 25826149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and antiproliferative and apoptosis-inducing activity of novel 3-substituted-3-hydroxy-2-oxindole compounds.
    Nazemi Moghaddam M; Jalal R; Zeraatkar Z
    In Vitro Cell Dev Biol Anim; 2018 Jan; 54(1):61-70. PubMed ID: 29124512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiandrogenic mechanisms of pesticides in human LNCaP prostate and H295R adrenocortical carcinoma cells.
    Robitaille CN; Rivest P; Sanderson JT
    Toxicol Sci; 2015 Jan; 143(1):126-35. PubMed ID: 25324206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis, molecular modeling, in vivo study and anticancer activity against prostate cancer of (+) (S)-naproxen derivatives.
    Birgül K; Yıldırım Y; Karasulu HY; Karasulu E; Uba AI; Yelekçi K; Bekçi H; Cumaoğlu A; Kabasakal L; Yılmaz Ö; Küçükgüzel ŞG
    Eur J Med Chem; 2020 Dec; 208():112841. PubMed ID: 32998089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
    Cai C; Chen S; Ng P; Bubley GJ; Nelson PS; Mostaghel EA; Marck B; Matsumoto AM; Simon NI; Wang H; Chen S; Balk SP
    Cancer Res; 2011 Oct; 71(20):6503-13. PubMed ID: 21868758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preselection of A- and B- modified d-homo lactone and d-seco androstane derivatives as potent compounds with antiproliferative activity against breast and prostate cancer cells - QSAR approach and molecular docking analysis.
    Kovačević SZ; Podunavac-Kuzmanović SO; Jevrić LR; Vukić VR; Savić MP; Djurendić EA
    Eur J Pharm Sci; 2016 Oct; 93():107-13. PubMed ID: 27503457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis, Anticancer Activity on Prostate Cancer Cell Lines and Molecular Modeling Studies of Flurbiprofen-Thioether Derivatives as Potential Target of MetAP (Type II).
    Yılmaz Ö; Bayer B; Bekçi H; Uba AI; Cumaoğlu A; Yelekçi K; Küçükgüzel ŞG
    Med Chem; 2020; 16(6):735-749. PubMed ID: 31203805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR/CYP17 for the treatment of prostate cancer.
    Hou Q; He C; Lao K; Luo G; You Q; Xiang H
    Steroids; 2019 Oct; 150():108384. PubMed ID: 30885648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of androstenediol-dependent LNCaP tumour growth by 17alpha-ethynyl-5alpha-androstane-3alpha, 17beta-diol (HE3235).
    Trauger R; Corey E; Bell D; White S; Garsd A; Stickney D; Reading C; Frincke J
    Br J Cancer; 2009 Apr; 100(7):1068-72. PubMed ID: 19337256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Silibinin derivatives as anti-prostate cancer agents: Synthesis and cell-based evaluations.
    Vue B; Zhang S; Zhang X; Parisis K; Zhang Q; Zheng S; Wang G; Chen QH
    Eur J Med Chem; 2016 Feb; 109():36-46. PubMed ID: 26748997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis of 17β-N-arylcarbamoylandrost-4-en-3-one derivatives and their anti-proliferative effect on human androgen-sensitive LNCaP cell line.
    Cortés-Benítez F; Cabeza M; Ramírez-Apan MT; Alvarez-Manrique B; Bratoeff E
    Eur J Med Chem; 2016 Oct; 121():737-746. PubMed ID: 27423983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CYP17A1 inhibitor abiraterone, an anti-prostate cancer drug, also inhibits the 21-hydroxylase activity of CYP21A2.
    Malikova J; Brixius-Anderko S; Udhane SS; Parween S; Dick B; Bernhardt R; Pandey AV
    J Steroid Biochem Mol Biol; 2017 Nov; 174():192-200. PubMed ID: 28893623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and molecular modeling of (4'R)- and (4'S)- 4'-substituted 2'-{[(E)-androst-5-en-17-ylidene]-methyl}oxazolines.
    Stulov SV; Mankevich OV; Novikov RA; Tkachev YV; Timofeev VP; Dugin NO; Pozdnev VF; Fedyushkina IV; Scherbinin DS; Veselovsky AV; Misharin AY
    Steroids; 2013 May; 78(5):521-7. PubMed ID: 23499823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel P450(17alpha) inhibitors: 17-(2'-oxazolyl)- and 17-(2'-thiazolyl)-androstene derivatives.
    Zhu N; Ling Y; Lei X; Handratta V; Brodie AM
    Steroids; 2003 Sep; 68(7-8):603-11. PubMed ID: 12957665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.